KGKagan Gungor

Kagan Gungor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kagan Gungor has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Genetic spectrum and genotype–phenotype associations in Paget's disease of bone: A nationwide multicenter study from Türkiye

    by Dilek Gogas Yavuz, Hazal Şalva, Pınar Ata, Ebru Arslan, Onur Hanoğlu, Mahsan Azimi, Zeliha Hekimsoy, Hakan Doğruel, Ramazan Sarı, Feyza Yener Öztürk, et al.

  • Open Access

    The risk of vertebral fractures in patients with differentiated thyroid cancer undergoing TSH suppression therapy

    by Dilek Gogas Yavuz, Ceyda Dincer Yazan, Zeliha Hekimsoy, Kadriye Aydin, Naile Gokkaya, Canan Ersoy, Berna Imge Aydogan, Aysen Akalin, Omercan Topaloglu, Esra Nur Ademoglu Dilekci, et al.

    Background: Suppression of thyroid-stimulating hormone (TSH) can adversely affect bone tissue in individuals with differentiated thyroid cancer (DTC). This study aims to examine bone mineral density (BMD) and vertebral fractures (VF) in DTC patients receiving levothyroxine (LT4) suppression therapy. Methods: A total of 990 patients with differentiated thyroid cancer who had undergone total thyroidectomy and received levothyroxine suppression therapy for a minimum of one year were included in the study. Clinical and laboratory data obtained at the most recent visit were extracted from patient records. Bone mineral density (BMD) measurements of the lumbar spine and femoral regions, assessed by dual-energy X-ray absorptiometry (DXA) within the preceding year, were recorded. When available, lateral vertebral radiographs were also evaluated. Results: The study included 990 patients with differentiated thyroid cancer (DTC). According to DXA results, 545(55.2%) had normal BMD, 363 (36.6%) had osteopenia, and 82 (8.2%) had osteoporosis. Osteoporotic patients were older and had lower BMI (p = 0.001 for both), while TSH levels were similar across groups. Among 476 patients with vertebral radiographs, 131 (27.5%) had moderate to severe vertebral fractures (VF). Fracture rates were significantly higher in patients with severe TSH suppression compared to other groups (p = 0.013). Patients with VF were older and had lower femoral neck and L1–L4 BMD (p = 0.001). Regression analysis showed that disease duration, FT4 levels, and femoral neck BMD were associated with fracture risk (p = 0.001). Multivariate analysis identified age, femoral neck BMD, L1–L4 BMD, and osteocalcin as independent predictors of osteoporosis (p = 0.001). TSH subgroups showed no differences in BMD values. Conclusion: Findings suggest that DTC patients undergoing TSH suppression have a significant risk of VF. Assessments of VF should be integrated into routine care for DTC survivors to ensure long-term skeletal safety.

  • Anti-Müllerian hormone and somatic ovarian function: a new perspective

    by Önder Çelik, Nilüfer Çelik, Aynur Ersahin, Nur Gungor, Kagan Gungor, Sudenaz Celik

    Purpose Anti-Müllerian hormone (AMH) is widely used as a clinical biomarker of ovarian reserve and is traditionallyinterpreted as a surrogate measure of remaining oocyte quantity. However, accumulating biological and clinicalevidence challenges this quantitative paradigm. AMH is exclusively produced by granulosa cells of growing folliclesrather than by primordial follicles themselves, suggesting that circulating AMH primarily refl ects somatic follicularactivity instead of dormant oocyte pool size. Here, we propose a conceptual framework redefi ning ovarian aging as aprocess that may be strongly infl uenced by progressive somatic ovarian dysfunction. Methods In this model, granulosa cells, stromal integrity, vascular support, immune regulation, and metabolicenvironment collectively form a somatic support network that determines follicular survival and developmentalcompetence. Disruption of this somatic ecosystem, through aging, surgery, chemotherapy, autoimmunity,environmental toxicants, smoking, or metabolic stress, results in reduced granulosa cell functionality, declining AMHsecretion, impaired follicle maturation, and secondary oocyte loss. Evidence from granulosa cell biology, controlledovarian stimulation, ovarian surgery, autoimmune ovarian disease, chemotherapy exposure, and fertility outcomestudies consistently demonstrates that AMH responds dynamically to changes in somatic ovarian health and doesnot reliably predict natural fecundability or absolute follicle number. Results Primordial follicle depletion progresses continuously throughout life, yet circulating AMH levels often showabrupt declines in response to somatic ovarian injury such as surgery, chemotherapy, or metabolic stress.Continuous primordial follicle attrition therefore does not translate into continuous AMH decline, supporting the viewthat AMH represents the functional cohort of biologically supported follicles rather than the total ovarian reserve. It isimportant to recognize, however, that ovarian reserve markers including AMH have limited predictive value fornatural fecundability with area under the curve values ranging from 0.60 to 0.65. Conclusion We introduce the concept of somatic ovarian function as an integrated framework for AMHinterpretation, proposing AMH as a biomarker of ovarian functional capacity. Reframing AMH from a purelyquantitative reserve marker to a functional systems biomarker that refl ects granulosa cell integrity, metabolichealth, and environmental infl uences may help reconcile longstanding clinical paradoxes and open new translationalavenues for fertility preservation, ovarian aging research, and therapeutic intervention.

  • Tissue Accessibility as a Missing Determinant of Immunomodulatory and Platelet‐Rich Plasma Therapy Success in Infertility: A Conceptual Framework

    by Onder Celik, Nilufer Celik, Nur Dokuzeylul Gungor, Aynur Ersahin, Kagan Gungor, Aziz Ihsan Tavuz, Sudenaz Celik

    Problem: Immunomodulatory agents (IVIG, intralipid, corticosteroids, and G‐CSF) and platelet‐rich plasma (PRP) are increasingly used in infertility despite inconsistent clinical outcomes. A critical but overlooked question is whether these agents exert their effects through systemic immune modulation or require direct access to target cells within the ovary and endometrium. Hypothesis: We propose that insufficient tissue accessibility, rather than intrinsic biological inefficacy, may contribute to inconsistent clinical outcomes. This framework examines the physical constraints governing therapeutic effectiveness if local action were necessary, while acknowledging that benefits may also be mediated systemically. Findings: Anatomical and biophysical barriers differ by administration route. For systemic agents, the vascular endothelium (continuous capillaries) restricts macromolecular extravasation via capacity‐limited transcytosis. For local agents, epithelial tight junctions (0.5–2 nm pores), follicular basal lamina (40–100 nm), granulosa cell layers (∼20 nm), and the zona pellucida (5–10 nm) create sequential barriers. Molecular size analysis suggests that large immunomodulators like IVIG (∼150 kDa, 10–15 nm) and intralipid particles (200–500 nm) face substantial limitations in reaching target compartments. PRP growth factors face identical barriers. By contrast, smaller molecules (<1 kDa) and FSH (∼30 kDa, 5 nm) penetrate more readily. Ovarian tissue stiffness (1.5–5 kPa in normal ovaries; 0.9–11.3 kPa in premature ovarian insufficiency) further impedes macromolecular diffusion. The proposed Mathematical Access Index integrates molecular size, barrier pore dimensions, and tissue stiffness to predict accessibility. Conclusion: Accessibility of immunomodulators and PRP growth factors to reproductive tissues is more limited than commonly assumed. If these therapies act predominantly through systemic immune modulation (e.g., Fc receptor saturation, Th1/Th2 modulation), direct tissue penetration may not be necessary. For PRP, observed effects likely result from indirect mechanisms (paracrine signaling, angiogenesis). Distinguishing between systemic and local mechanisms is essential. Until pharmacokinetic studies quantify drug concentrations in reproductive tissues, clinical use should remain cautious.


  • Open Access

    Relationship of thyroid hormones and metabolic parameters in euthyroid women

    by Fatma Nur Yürekten Sıcakyüz, Furkan Alp Eren, Kağan Güngör, Hacer Hicran Mutlu

    Objective: Thyroid hormones play a role in metabolic regulation, yet their associations with obesity and insulin resistance in euthyroid individuals remain unclear. This study aimed to evaluate the relationship between thyroid-stimulating hormone (TSH), fT3, fT4, and the fT3/fT4 ratio with metabolic parameters in euthyroid women. Methods: In this retrospective cross-sectional study, 236 euthyroid women aged 18–65 were recruited from a tertiary hospital in Istanbul between May and September 2023. Participants were categorized as individuals with normal weight, overweight, or obesity. Thyroid hormones and metabolic parameters (waist circumference, triglycerides, HDL-C, insulin resistance) were analyzed. Statistical analyses included correlation tests and ANCOVA for age adjustment. Results: No significant differences in thyroid hormone levels were found across BMI groups after adjusting for age. TSH was positively correlated with BMI and triglyceride levels. fT3 and the fT3/fT4 ratio were positively associated with insulin resistance and negatively associated with HDL-C. Conclusion: fT3 and the fT3/fT4 ratio may reflect metabolic alterations in euthyroid individuals. These findings highlight the potential relevance of thyroid hormone evaluation in assessing metabolic risk, especially among individuals with obesity or insulin resistance. Further multicenter studies are warranted.

  • Open Access

    The risk of vertebral fractures in patients with differentiated thyroid cancer undergoing TSH suppression therapy

    by Dilek Gogas Yavuz, Ceyda Dincer Yazan, Zeliha Hekimsoy, Kadriye Aydin, Naile Gokkaya, Canan Ersoy, Berna Imge Aydogan, Aysen Akalın, Omercan Topaloglu, Esra Nur Ademoglu Dilekci, et al.

    Backgound: Suppression of thyroid-stimulating hormone (TSH) can adversely affect bone tissue in individuals with differentiated thyroid cancer (DTC).In a multi-center setting, this study aim to examine vertebral fractures (VF) and bone mineral density (BMD) in DTC patients receiving levothyroxine (LT4) suppression therapy. Methods: Clinical measurements done in the last visit, laboratory and radiologic data extracted from patients files. Serum TSH concentrations were divided into four groups based on the American Thyroid Association’s guidelines for TSH suppression: 0.01 mu/L, 0.01-0.1, 0.1–0.5 mu/L, and >0.5 mu/L. Within the preceding year, the BMD measurements obtained in the lumbar and femoral regions with a DXA scanner were recorded. Lateral spinal X-rays obtained within the previous year were evaluated. Results: The study comprised 990 people with DTC. The DXA showed 545 patients with normal BMD, 82 (8.2%) with osteoporosis, and 363 (36.6%). patients had osteopenia. The osteoporotic group exhibited older age (p = 0.001), lower BMI (p = 0.001), and comparable TSH levels compare to the osteopenia and normal BMD groups. In 476 lateral vertebral x-rays, 200 (42%), 131 (27.5%) were significant or severe VF. The severe TSH suppression group had a greater fracture rate than the moderate, mild, and non-suppressed groups(p=0.013). VF patients were older (p = 0.001) and had lower femur neck and L1-L4 BMD. Disease duration, FT4 level, and femur neck BMD affected fracture risk (p = 0.001, pseudo R2: 0.028). Age, femur neck BMD, L1-L4 BMD, and osteocalcin levels were linked with osteoporosis in a multivariate analysis (p = 0.001, pseudo R2: 0.427). TSH subgroups had similar femur neck (p = 0.61) and L1-L4 BMD (p = 0.89). Conclusion: Findings suggest that DTC patients undergoing TSH suppression have a significant risk of VF. Assessment of VF should be integrated into the routine care of DTC survivors to ensure long-term skeletal safety.

  • Navigating Gynecological Oncology with Different Versions of ChatGPT: A Transformative Breakthrough or the Next Black Box Challenge?

    by Nur Dokuzeylul Gungor, Fatih Sinan Esen, Tolga Tasci, Kagan Gungor, Kaan Cil

    Introduction: The study evaluates the performance of large language model versions of ChatGPT – ChatGPT-3.5, ChatGPT-4, and ChatGPT-Omni – in addressing inquiries related to the diagnosis and treatment of gynecological cancers, including ovarian, endometrial, and cervical cancers. Methods: A total of 804 questions were equally distributed across four categories: true/false, multiple-choice, open-ended, and case-scenario, with each question type representing varying levels of complexity. Performance was assessed using a six-point Likert scale, focusing on accuracy, completeness, and alignment with established clinical guidelines. Results: For true/false queries, ChatGPT-Omni achieved accuracy rates of 100% for easy, 98% for medium, and 97% for complicated questions, higher than ChatGPT-4 (94%, 90%, 85%) and ChatGPT-3.5 (90%, 85%, 80%) (p = 0.041, 0.023, 0.014, respectively). In multiple-choice, ChatGPT-Omni maintained superior accuracy with 100% for easy, 98% for medium, and 93% for complicated queries, compared to ChatGPT-4 (92%, 88%, 80%) and ChatGPT-3.5 (85%, 80%, 70%) (p = 0.035, 0.028, 0.011). For open-ended questions, ChatGPT-Omni had mean Likert scores of 5.8 for easy, 5.5 for medium, and 5.2 for complex levels, outperforming ChatGPT-4 (5.4, 5.0, 4.5) and ChatGPT-3.5 (5.0, 4.5, 4.0) (p = 0.037, 0.026, 0.015). Similar trends were observed in case-scenario questions, where ChatGPT-Omni achieved scores of 5.6, 5.3, and 4.9 for easy, medium, and hard levels, respectively (p = 0.017, 0.008, 0.012). Conclusions: ChatGPT-Omni exhibited superior performance in responding to clinical queries related to gynecological cancers, underscoring its potential utility as a decision support tool and an educational resource in clinical practice.


  • Open Access

    Correlation of serum leptin and ghrelin levels with endocrine and reproductive parameters in women with clomiphene citrate resistant polycystic ovary syndrome

    by Arzu Yurci, Nur Dokuzeylül Güngör, Kağan Güngör, Şafak Hatırnaz

    Objective: To investigate the changes in serum ghrelin and leptin levels in patients with clomiphene-resistant polycystic ovary syndrome (PCOS). Materials and Methods: Thirty-five patients who could not achieve ovulation or pregnancy despite using 150 mg/day of clomiphene citrate (CC) participated in the study. Thirty-five patients who were compatible with the study group in terms of age and body mass index (BMI) but did not have clinical and laboratory findings of PCOS constituted the control group. On the third day of the cycle, in addition to the basal hormone profile, ghrelin and leptin levels were also measured. Patients in both groups went to IVF/ICSI. Basal hormone values, leptin, ghrelin, metabolic, demographic parameters, and clinical pregnancy rates were correlated. Results: Patients in both groups were recorded to be similar in terms of age (29.4 +/- 0.11 vs 28.5 +/- 7.30), BMI (24.3 +/- 3.07 vs 23.8 +/- 1.55), and infertility time (6.14 +/- 4.30 vs 6.03 +/- 1.28). Serum ghrelin levels of the PCOS group were significantly lower than the control group (0.48 +/- 2.21 vs 1.19 +/- 4.02) Serum leptin levels of the PCOS group were significantly higher than the control patients (45.6 +/- 304 vs 16.5 +/- 0.32). Serum leptin levels and BMI (r=0.65, p<0.01) A positive correlation was found between luteinizing hormone (LH) (r=0.53, p<0.02), and insulin resistance (r=0.74, p<0.03). There was a negative (r=-0.76, p<0.03) correlation between serum ghrelin and LH. A positive and significant correlation was found between serum ghrelin, testosterone, mature oocre, and implantation rates. Conclusion: Serum ghrelin correlates with fertility outcomes in women with CC-resistant PCOS undergoing IVF/ICSI.


  • Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients

    by Dilek Gogas Yavuz, Ceyda D. Yazan, Zeliha Hekimsoy, Kadriye Aydin, Naile Gokkaya, Canan Ersoy, Aysen Akalın, Omercan Topaloglu, Berna I. Aydogan, Esra N. A. Dilekci, et al.

    Objective: Thyroid‐stimulating hormone (TSH) suppression treatment can induce signs and symptoms of hyperthyroidism and hypothyroidism due to inappropriate treatment or poor compliance to the treatment. The current study aimed to investigate TSH levels, frequency of being on target TSH, adherence to levothyroxine (LT4) suppression treatment in differentiated thyroid cancer (DTC) patients after surgery in a multicentric setting.Design and Patients: This multicentric cross‐sectional study was conducted at 21 medical centres from 12 cities in Turkey. DTC patients followed at least one year in the same center included in the study. Clinical data, serum TSH, free thyroxine (FT4), thyroglobulin (Tg) and anti‐Tg levels were recorded during the most recent visit. Body mass index, systolic and diastolic blood pressures, pulse rate were measured. LT4 doses were recorded and doses per kilogram of bodyweight were calculated. Pill ingestion habits recorded and adherence to the therapy were evaluated using the Morisky Medication Adherence Scale and categorized as good, moderate or poor compliant based on their scores. Risk stratification forpredicting the disease persistance and/or reccurence was assessed using the American Joint Committee on Cancer‐7th edition thyroid cancer staging calculator. TSH serum concentrations were classified as severe suppression (TSH < 0.01 mU/L), moderate suppression (TSH: 0.01–0.1 mU/L), mild suppression (TSHL 0.1–0.5 mU/L), euthyroid (TSH: 0.5–4 mU/L) and hypothyroid (TSH > 4 mU/L). TSH levels can also be classified as on being on target, under the target, or beyond over the target, according to the American Thyroid Association recommendations.Results: A group of 1125 patients (F/M: 941/184, 50.7 ± 11.7 years) were included in the study. The mean LT4 daily dosage was 132.4 ± 39.6 mcg/day. TSH levels showed severe suppression in 99 (%8.8) patients, moderate suppression in 277 (%24.6) patients and mild suppression in 315 (%28) patients and euthyroid range in 332 (%29.5) patients and hypothyroid range in 97 (8.6%). TSH levels were in target in 29.2% of the patients 20.4% of the patients were undertreated, 50.4% overtreated. The daily LT4 dose and LT4 dose/kg were significantly higher in the severe suppression group (p < .001, p < .001). According to the Morisky scale, 564 patients (50.1%) were good compliant, 368 patients (32.7%) were moderate compliant, and 193 patients (17.1%) were noncompliant. Patients with poor compliance need a higher dose of LT4 compared to the good compliance group (p < .001). TSH levels of patients with good compliance were 0.67 ± 1.96 mU/L and TSH with poor compliance was 2.74 ± 7.47 mU/L (p < .001). TSH levels were similar in patients on fixed and alternating dosages.Conclusion: In 29.2% of the DTC patients, serum TSH levels were at target levels. Remaining of the study group have TSH levels under or over treatment range, exposing the patient to medication side effects. Majorty of the study group 82.8% have good or moderate adherence to LT4 therapy. Reaching TSH targets requires simplified and applicable guidelines and following the guideline recommendations.


  • Open Access

    Ovarian drilling down-regulates endometrial nuclear factor-κB p65 expression in women with PCOS: A prospective case-control study

    by Nur Dokuzeylül Güngör, Kağan Güngör, Arzu Yurci, Kaan Cil, Şafak Hatırnaz

    To investigate the impact of laparoscopic ovarian drilling (LOD) on the expression of endometrial NFκB p65 (Rel A) in women with clomiphene-resistant polycystic ovary syndrome (PCOS). The study group comprised 25 normal-weight women with PCOS undergoing LOD and 14 control women without PCOS. Endometrial NF-κB p65 levels evaluated before and after LOD following immunohistochemical staining. The semiquantitative method was used to evaluate the intensity of NF-κB p65 levels. NF-κB p65 was found to higher in the endometrium of patients with PCOS compared to controls. LOD leads to significant down-regulation in endometrial NF-κB p65 expression. NF-κB p65 expression of PCOS and fertile control were similar after LOD. After LOD, H-score values decreased approximately 3-fold. The H-score of the control subjects was lower than the preoperative and postoperative H-score values of the control women with ovarian cyst. Expression of endometrial NF-κB p65 did not change following ovarian cystectomy. The laterality of the ovarian cyst did not cause any change in preoperative H-score values. By downregulating the endometrial NF-κB p65 expression LOD improved physiological inflammation in women with PCOS.